BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12843857)

  • 21. [Unilateral acneiform rash in facial palsy].
    Kerob D; Hennequin V; Bousquet G; Behm E; Lebbe C
    Ann Dermatol Venereol; 2010 Nov; 137(11):727-9. PubMed ID: 21074658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acneiform skin eruption in patients with metastatic colorectal carcinoma].
    Gethöffer K; Schneider LA; Peters T; Weber L; Scharffetter-Kochanek K
    Hautarzt; 2006 Jul; 57(7):628-31. PubMed ID: 16034631
    [No Abstract]   [Full Text] [Related]  

  • 23. [Acneiform eruption secondary to cetuximab].
    Herrera-Acosta E; Martín-Ezquerra G; Iglesias M; Umbert P
    Actas Dermosifiliogr; 2005 May; 96(4):252-4. PubMed ID: 16476378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole-induced acneiform eruption.
    Mishra B; Praharaj SK; Prakash R; Sinha VK
    Gen Hosp Psychiatry; 2008; 30(5):479-81. PubMed ID: 18774434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab-induced acne.
    Molinari E; De Quatrebarbes J; André T; Aractingi S
    Dermatology; 2005; 211(4):330-3. PubMed ID: 16286741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
    Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
    J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
    Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
    Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
    Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
    Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
    Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
    J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acneiform eruption secondary to cetuximab with pseudomalignant histopathological changes].
    Vidal-Olmo I; Bassas-Vila J; Herrera-Acosta E; Umbert-Millet P
    Actas Dermosifiliogr; 2008 Mar; 99(2):159-60. PubMed ID: 18346444
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment with adapalene of cetuximab-induced acneiform eruptions.
    Taguchi K; Fukunaga A; Okuno T; Nishigori C
    J Dermatol; 2012 Sep; 39(9):792-4. PubMed ID: 22168666
    [No Abstract]   [Full Text] [Related]  

  • 35. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
    Fernandez-Galar M; España A; López-Picazo JM
    Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe acneiform rash.
    Yamamoto DS; Viale PH; Zhao G
    Clin J Oncol Nurs; 2004 Dec; 8(6):654-6. PubMed ID: 15637959
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
    Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
    J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 40. Acneiform eruption following molecular targeted chemotherapy.
    Vaccaro M; Barbuzza O; Pollicino A; Guarneri C
    Intern Med J; 2011 Apr; 41(4):361-2. PubMed ID: 21507168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.